Akèy › Obèsite › Arizona › Phoenix
Etid klinik pou Obèsite nan Phoenix, AZ
22 etid pou Obèsite ap chèche patisipan nan sit nan ak bò kote Phoenix (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Early Tracking of Childhood Health Determinants (ETCHED) Study
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- NIDDK, Phoenix, Phoenix
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Ap rekriteFaz 3
- RIO Clinical Trials - Phoenix, Phoenix
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Ap rekriteFaz 3
- Research Site, Phoenix
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Ap rekriteFaz 3
- Synexus Clinical Research US, Inc., Phoenix
- Medical Advancement Centers of Arizona, Phoenix
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Ap rekriteFaz 3
- Elite Clinical Studies, LLC, Phoenix
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
Ap rekriteVolontè an sante akeyi
- NIDDK, Phoenix, Phoenix
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Ap rekriteFaz 3
- AURORA-1 Clinical Site, Phoenix
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Ap rekriteFaz 3
- AURORA-2 Clinical Site, Phoenix
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Ap rekriteFaz 3
- HonorHealth, Phoenix
- Medical Advancement Centers of Arizona, Phoenix
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Ap rekriteFaz 2
- Helios Clinical Research - Phoenix, Phoenix
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Ap rekriteFaz 3Volontè an sante akeyi
- ACCOMPLISH-2 Research Site, Phoenix
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Ap rekriteFaz 2
- Synexus Clinical Research US, Inc., Phoenix
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Ap rekriteFaz 4
- Medical Dermatology Specialists, Phoenix
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Ap rekriteFaz 3
- Kailera Clinical Site, Phoenix
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Ap rekriteFaz 3
- Kailera Clinical Site, Phoenix
The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure
Ap rekriteVolontè an sante akeyi
- NIDDK, Phoenix, Phoenix
Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity
Ap rekriteEtid obsèvasyon
- Exponent Phoenix, Phoenix
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Ap rekriteFaz 3
- Honor Health, Phoenix
- Arizona Research Center, Phoenix
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Ap rekriteFaz 3
- ACCOMPLISH-1 Research Site, Phoenix
Fibrosis Lessens After Metabolic Surgery
Ap rekriteFaz 4Volontè an sante akeyi
- Banner Health Center, Phoenix
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Ap rekriteFaz 3
- Arizona Research Center, Inc., Phoenix
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
Ap rekriteFaz 3
- The University of Arizona College of Medicine- Phoenix, Phoenix
Etid Obèsite nan lòt vil
- Houston, TX43 etid
- Chicago, IL41 etid
- New York City, NY40 etid
- San Antonio, TX40 etid
- Washington, DC33 etid
- Orlando, FL31 etid
- Dallas, TX30 etid
- Boston, MA28 etid
- Las Vegas, NV27 etid
- Miami, FL27 etid
- Baltimore, MD25 etid
- Jacksonville, FL25 etid
Lòt etid nan Phoenix
- Kansè nan tete25 etid
- Kansè kolorektal25 etid
- Kansè Poumon ki pa ti selil20 etid
- Kansè Metastatik20 etid
- Ensifizyans kadyak18 etid
- Kansè pwostat17 etid
- Kansè (tout kalite)17 etid
- Myelom Miltip16 etid
- Kansè pankreyas16 etid
- Maladi kadyovaskilè16 etid
- Maladi Alzheimer15 etid
- Sipwa15 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.